NK Cell Therapy for Oral Precancerous Lesions
Part of Cancer clinical trials.
This early-stage trial tests a new type of immune cell therapy (called CAR/IL-15 NK cells) designed to target and destroy precancerous lesions in the mouth. The therapy may help prevent these lesions from becoming cancer or coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed precancerous lesions in your mouth (dysplasia or early intraepithelial neoplasia) that are visible and accessible for injection
- Your lesions must show TROP2 protein expression (a marker the therapy targets)
- Age 18 or older with good overall health and normal organ function
- No active cancer at enrollment; history of head/neck cancer is acceptable if no signs of disease now
- At least 2 weeks since chemotherapy, 3 days since targeted drugs, or 3 months since any prior cell therapy
- Willing to stay within 2 hours of the treatment center for the first 4 weeks after therapy and commit to blood tests and biopsies
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new kind of immune cell therapy (NK cells) designed to target and attack stomach cancer that has spread to the lining of the abdomen. It combines this with standard surgery and chemotherapy to see if it can help control the cancer.
This trial tests a new type of cell therapy using your own immune cells (NK cells) that are specially engineered to attack cancer cells that have a protein called TROP2. It is for people with advanced solid tumors that have not responded to standard treatments.
This trial tests a combination of two experimental treatments: special immune cells (NK cells) and a cancer-targeting drug called T-Dxd. It's for patients with breast cancer that hasn't responded to standard treatments and has spread or cannot be surgically removed.
This trial tests a new combination of specially grown immune cells (NK cells) plus two drugs that help them attack cancer. It's for people with a type of B-cell lymphoma that came back after at least two prior treatments or a stem cell transplant, and who have either failed or are not eligible for CAR-T cell therapy.
This trial tests a new type of cell therapy using natural killer cells (immune cells) that are designed to recognize and attack head and neck cancer cells. The therapy targets two specific proteins (EGFR and HER2) found on cancer cells and is for patients whose cancer has returned or spread despite previous treatments.
This study tests a new type of CAR-T cell therapy that targets a protein called Trop2 found on some head and neck cancer cells. It's for people who have tried standard treatments and need a new option.
Hear when a new Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.